Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.3SBio, a biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products primarily in China, has submitted its application for a phase I clinical trial for NuPIAO to the Chinese State Food and Drug Administration (SFDA).
Subscribe to our email newsletter
The company claims that NuPIAO is a highly glycosylated ESA (erythropoiesis-stimulating agent), with extended half-life and increased biologic activity.
The pre-clinical results showed a positive pharmacokinetic profile which would allow a once weekly injection schedule of NuPIAO in humans. NuPIAO is expected to be investigated to treat anemia associated with both chronic kidney disease and cancer.
Jing Lou, CEO of 3SBio, said: “This submission represents another important milestone in our effort to extend our EPO franchise and continue to serve the needs of patients in China. It is a direct result of our dedicated R&D effort to generate an innovative pipeline and create long term value for shareholders.”